Clinical Trials | June 04, 2024
Merck's oncology pipeline of DDRi and ADC poised to advance cancer treatment
Merck shared updates on the company’s oncology pipeline and focused R&D approach
Merck shared updates on the company’s oncology pipeline and focused R&D approach
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
These abstracts report on the company's three lead drug candidates, including olverembatinib
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Subscribe To Our Newsletter & Stay Updated
